For new clinical trials we expect approximately 15 million, with the cost of new packaging for the first million units being 2.5 million and the cost of new marketing being 100 million. The total is approximately $117.5 million for this new venture. The potential growth rate is 25% for children taking Kineret. The company earned $4.5 billion and a 25% increase at a reduced rate of 1,500 per unit would net the company about $600 million. $600 million minus the new venture cost of $117.5 million leaving the company with a profit of approximately $482.5 million. This seems like it could be a venture worth looking at